Sarepta Therapeutics $SRPT

Health Care · NASDAQ

$13.33
-0.84 (-5.93%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Nov 6, 2026, the first target we tracked for SRPT.

Sarepta Therapeutics (SRPT) is trading down at $13.33 (-5.93%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on SRPT

One firm's current price target on Sarepta Therapeutics: $18 — 35% above the current $13.3. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateNov 6, 2026 FirmBaird RatingNeutral · lowers Targetat $17.8 · $18 +1% Horizonby Nov 2027 StatusOpen

Entry price $17.8, the close nearest Nov 6, 2026, when the target was reported; the target is +1% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 6, 2027.

Source Baird cuts Sarepta Therapeutics stock price target on growth concerns Investing.com · Nov 6, 2026 · opens the publisher's site
Baird lowered its price target on Sarepta Therapeutics to $18.00 from $20.00

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Sarepta Therapeutics revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$2.20B$741.6M−$715.1MFY2016 revenue: $5.42MFY2016 net income: −$267.3M · Net margin −4930.2%'16FY2017 revenue: $154.6MFY2017 net income: −$50.7M · Net margin −32.8%'17FY2018 revenue: $301.0MFY2018 net income: −$361.9M · Net margin −120.2%'18FY2019 revenue: $380.8MFY2019 net income: −$715.1M · Net margin −187.8%'19FY2020 revenue: $540.1MFY2020 net income: −$554.1M · Net margin −102.6%'20FY2021 revenue: $701.9MFY2021 net income: −$418.8M · Net margin −59.7%'21FY2022 revenue: $933.0MFY2022 net income: −$703.5M · Net margin −75.4%'22FY2023 revenue: $1.24BFY2023 net income: −$536.0M · Net margin −43.1%'23FY2024 revenue: $1.90BFY2024 net income: $235.2M · Net margin 12.4%'24FY2025 revenue: $2.20BFY2025 net income: −$713.4M · Net margin −32.5%'25−9.8%0%10%20%30%FY2016 net margin: −4930.2% (off the scale, which stops at −9.8%)FY2017 net margin: −32.8% (off the scale, which stops at −9.8%)FY2018 net margin: −120.2% (off the scale, which stops at −9.8%)FY2019 net margin: −187.8% (off the scale, which stops at −9.8%)FY2020 net margin: −102.6% (off the scale, which stops at −9.8%)FY2021 net margin: −59.7% (off the scale, which stops at −9.8%)FY2022 net margin: −75.4% (off the scale, which stops at −9.8%)FY2023 net margin: −43.1% (off the scale, which stops at −9.8%)FY2024 net margin: 12.4%FY2025 net margin: −32.5% (off the scale, which stops at −9.8%)
Sarepta Therapeutics annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$5.42M$154.6M$301.0M$380.8M$540.1M$701.9M$933.0M$1.24B$1.90B$2.20B
Growth (year over year)+332.6%+2751.6%+94.7%+26.5%+41.8%+30.0%+32.9%+33.3%+53.0%+15.6%
Gross profit$5.29M————————$2.17B
Gross margin97.6%————————98.8%
Operating income−$266.7M−$171.6M−$343.6M−$705.6M−$564.2M−$459.7M−$536.2M−$267.8M$218.1M−$699.8M
Operating margin−4920.3%−111.0%−114.1%−185.3%−104.5%−65.5%−57.5%−21.5%11.5%−31.8%
Net income−$267.3M−$50.7M−$361.9M−$715.1M−$554.1M−$418.8M−$703.5M−$536.0M$235.2M−$713.4M
Net margin−4930.2%−32.8%−120.2%−187.8%−102.6%−59.7%−75.4%−43.1%12.4%−32.5%
EPS (diluted)−$5.49−$0.86−$5.46−$9.71−$7.11−$5.15−$8.03−$5.80$2.34−$7.13
Balance sheet
Cash and equivalents$122.4M$599.7M$370.8M$835.1M$1.50B$2.12B$966.8M$428.4M$1.10B$801.3M
Total assets$424.1M$1.31B$1.64B$1.82B$2.98B$3.15B$3.13B$3.26B$3.96B$3.35B
Total liabilities$87.4M$518.7M$609.8M$1.00B$2.22B$2.22B$2.74B$2.41B$2.44B$2.21B
Long-term debt$17.7M$431.1M$420.6M——$563.7M$1.54B$1.24B$1.14B$829.0M
Shareholders' equity$336.7M$789.2M$1.03B$818.2M$761.8M$928.0M$384.9M$859.3M$1.53B$1.14B
Cash flow
Operating cash flow−$245.8M−$232.0M−$388.7M−$456.5M$107.5M−$443.2M−$325.3M−$501.0M−$205.8M−$205.5M
Capital expenditure$5.34M$12.0M$61.2M$59.6M$82.2M$38.5M$30.8M$76.1M$137.0M$102.0M
Free cash flow−$251.2M−$244.0M−$449.8M−$516.1M$25.3M−$481.7M−$356.2M−$577.1M−$342.7M−$307.5M
Share buybacks———————$0$0$25.0M

From Sarepta Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Sarepta Therapeutics in the news

Nov 6, 2026 Investing.com Baird cuts Sarepta Therapeutics stock price target on growth concerns Target

About Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

Source: Wikipedia — Sarepta Therapeutics

Headquarters
Cambridge, Massachusetts From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →